Correlation Between ADMA Biologics and Corvus Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both ADMA Biologics and Corvus Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining ADMA Biologics and Corvus Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between ADMA Biologics and Corvus Pharmaceuticals, you can compare the effects of market volatilities on ADMA Biologics and Corvus Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in ADMA Biologics with a short position of Corvus Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of ADMA Biologics and Corvus Pharmaceuticals.

Diversification Opportunities for ADMA Biologics and Corvus Pharmaceuticals

-0.06
  Correlation Coefficient

Good diversification

The 3 months correlation between ADMA and Corvus is -0.06. Overlapping area represents the amount of risk that can be diversified away by holding ADMA Biologics and Corvus Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Corvus Pharmaceuticals and ADMA Biologics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on ADMA Biologics are associated (or correlated) with Corvus Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Corvus Pharmaceuticals has no effect on the direction of ADMA Biologics i.e., ADMA Biologics and Corvus Pharmaceuticals go up and down completely randomly.

Pair Corralation between ADMA Biologics and Corvus Pharmaceuticals

Given the investment horizon of 90 days ADMA Biologics is expected to generate 0.79 times more return on investment than Corvus Pharmaceuticals. However, ADMA Biologics is 1.27 times less risky than Corvus Pharmaceuticals. It trades about 0.08 of its potential returns per unit of risk. Corvus Pharmaceuticals is currently generating about -0.15 per unit of risk. If you would invest  1,745  in ADMA Biologics on December 27, 2024 and sell it today you would earn a total of  225.00  from holding ADMA Biologics or generate 12.89% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

ADMA Biologics  vs.  Corvus Pharmaceuticals

 Performance 
       Timeline  
ADMA Biologics 

Risk-Adjusted Performance

Modest

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in ADMA Biologics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak primary indicators, ADMA Biologics sustained solid returns over the last few months and may actually be approaching a breakup point.
Corvus Pharmaceuticals 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Corvus Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

ADMA Biologics and Corvus Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with ADMA Biologics and Corvus Pharmaceuticals

The main advantage of trading using opposite ADMA Biologics and Corvus Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if ADMA Biologics position performs unexpectedly, Corvus Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corvus Pharmaceuticals will offset losses from the drop in Corvus Pharmaceuticals' long position.
The idea behind ADMA Biologics and Corvus Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Other Complementary Tools

Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format